

Assessment of Drug-Resistant Tuberculosis within the Decentralized Health System in Kenya and the Associated Treatment Outcomes

Mutabari David ^{*1}, Dr. Idah Orowe ², Dr. Anthony Karanja ³, Dr. Hillary Kipruto ⁴

¹Department of Public & Global Health, University of Nairobi, Kenya.

²Department of Mathematics, University of Nairobi, Kenya.

³Department of Mathematics, Maasai Mara University, Kenya.

⁴Department of Public & Global Health, University of Nairobi, Kenya.

*Corresponding author; Mutabari David; davidmutabari42@gmail.com

Abstract

Background: In Kenya, health is a devolved function that county governments run. Tuberculosis is managed at the county level in coordination with the National Leprosy Tuberculosis and Lung Disease Program (NLTP), which has a mission of End TB Strategy to achieve a 95% decline in deaths due to tuberculosis compared with the 2015 baseline and reach an equivalent 90% reduction in tuberculosis incidence rate. **Methods:** This was a retrospective study that included patients who tested positive for drug-resistant tuberculosis from 2014 to 2019. Data was sourced from NLTP Electronic Medical Records. After abstraction, the data was entered into Excel and analyzed through STATA software version 13. **Results:** Of the 2674 enrolled patients in total, there were more males affected with DRTB at 64 % compared to the female patients. The public facilities carried the immense burden of diagnosis and treatment of the patient, having a cumulative number of 83 %, while the prison sector had the lowest number. For the resistance pattern, the new, relapse, and failure of first-line drugs accounted for most drug-resistant cases at 80 %, with only 65 % of the total cases having been done a gene-expert test at the point of screening. **Conclusion:** Kenya's devolved health system needs more coordinated support from the national government to the county health units for TB surveillance. Regional centralized laboratories for diagnosis and monitoring of TB would reduce the time it takes for samples to come to Nairobi for testing, which takes time before patents are initiated on treatment.

Keywords: Drug resistant tuberculosis; devolution; WHO.

Introduction

The drafters of the 2010 Kenyan constitution chose to devolve functions to 47 newly created counties based on Kenya's 1992 district framework (Republic of Kenya, 1992). These new functions would be administered by locally elected politicians and civil servants, with formula-driven funding from the national government and limited locally generated revenue ^[1]. In Kenya, health is a devolved function that county governments run, and tuberculosis is managed at the county level in coordination with the National Leprosy Tuberculosis and Lung Disease Program (NLTP). According to the National TB Prevalence Survey Report 2016, the burden of TB in Kenya was 426 cases per 100,000 population ^[2]. An estimated 147,000 people fell ill with TB in 2019. Only 86,385 were diagnosed, treated, and notified of the national TB program, which undermines the End TB Strategy to achieve a 95% decline in deaths due to tuberculosis compared with the 2015 baseline and reach an equivalent 90% reduction in tuberculosis incidence rate ^[3].

In 2018, WHO estimated that the global burden of TB was 10 million cases and 1.45 million deaths ^[4], with an estimated

500,000 cases being resistant to rifampicin. Second-line treatment for these cases is costly, with an average treatment success of only 56%, compared to 85% for drug-sensitive TB ^[5]. TB continues to be a significant public health problem, with the African region accounting for 23% of new cases and 31% of TB-related deaths ^[6]. It remains undiagnosed due to inadequate access to diagnostic tools that simultaneously detect tuberculosis and screen for resistance ^[7]. In Kenya, W.H.O estimates that 1.3% of new T.B. cases and 4.4% of previously treated T.B. cases have MDR/RR T.B. According to the Kenya drug resistance survey of 2014, the prevalence of isoniazid mono-resistance among new patients was 5.5% ^[8]. In 2021, the estimated TB incidence in Kenya was 133,000, and an estimated 32,000 people died from TB. Kenya notified 76,010 incident TB cases, and 64 % of the total notified bacteriologically confirmed individuals with TB were tested for rifampicin resistance ^[9].

Methodology

Study design: Retrospective cohort study. **Study site:** Data were collected retrospectively from all health facilities accredited by the National Tuberculosis and Leprosy Board for drug-resistant

tuberculosis treatment. **Study population:** It included all patients who had tested positive for drug-resistant tuberculosis from 2014 to 2019. **Data abstraction and analysis:** Data was sourced from the Kenya National Tuberculosis and Leprosy Board's Electronic Medical Records (TIBU-System). After abstraction, the data was entered into Excel and analyzed through STATA software version 13. **Data analysis:** Descriptive statistics were used to describe the socio-demographic and disease characteristics of the study participants. The Cox proportional hazards regression model was used to determine factors associated with sputum conversion time from the devolved health units. Adjusted Hazard Ratios (AHR) with 95% confidence intervals were computed, and statistical significance was declared when it was significant at a 5% level (p-value < 0.05).

Ethical Consideration

Ethical clearance was obtained from the Kenyatta National Hospital/University of Nairobi ethics board under ethical review number P378|05|2019. A formal letter was also written to the

National Leprosy, Tuberculosis, and lung disease program to abstract data from their system.

Results

For this study, we included DRTB patients who had been enrolled for treatment in the 47 counties DRTB treatment centers registered under the NLTP, including the sector of care (private, mission, public), type of resistance pattern a patient was enrolled on for treatment, registration group (new, relapse, failure of first-line drugs) country of treatment, age group a patient enrolled on (below 20, 20-30, 31-49, above 50), and the treatment outcome for the enrolled patients.

1. Enrollments

In total, we had 2674 patients. We saw a progressive increase from 2014 to 2018, with a significant drop in 2019 cumulatively and quarterly compared to the previous year. 2018 had a peak of registered patients on treatment immediately after Kenya's first TB survey was released on a national-level platform.

Table 1: Yearly enrolment for the DRTB from 2014 to 2019 per quarter

| Year | Quarter | | | | Total |
|--------------|------------|------------|------------|------------|--------------|
| | 1 | 2 | 3 | 4 | |
| 2014 | 87 | 73 | 52 | 102 | 314 |
| 2015 | 93 | 117 | 126 | 119 | 455 |
| 2016 | 121 | 113 | 108 | 112 | 454 |
| 2017 | 164 | 118 | 130 | 136 | 548 |
| 2018 | 155 | 240 | 194 | 118 | 707 |
| 2019 | 177 | 19 | 0 | 0 | 196 |
| Total | 797 | 680 | 610 | 587 | 2,674 |

2. Care and Treatment Centers

As with the national guidelines for leprosy, tuberculosis, and lung disease, all centers that treat drug-resistant tuberculosis had to be registered by the body for ease of drug supply, monitoring, and

documentation of treatment outcomes. In general, all 47 counties had treatment centers, including private, mission, and public facilities.

Table 2: Treatment and care centers of DRTB in Kenya

| Valid | Freq. | Percentage | Valid | Cum. |
|-------------------|-------|------------|-------|-------|
| 1 Baringo | 31 | 1.16 | 1.16 | 1.16 |
| 2 Bomet | 35 | 1.31 | 1.31 | 2.47 |
| 3 Bungoma | 46 | 1.72 | 1.72 | 4.19 |
| 4 Busia | 32 | 1.20 | 1.20 | 5.39 |
| 5 Elgeyo Marakwet | 15 | 0.56 | 0.56 | 5.95 |
| 6 Embu | 57 | 2.13 | 2.13 | 8.08 |
| 7 Garissa | 134 | 5.01 | 5.01 | 13.09 |
| 8 Homa Bay | 59 | 2.21 | 2.21 | 15.30 |
| 9 Isiolo | 25 | 0.93 | 0.93 | 16.23 |
| 10 Kajiado | 42 | 1.57 | 1.57 | 17.80 |
| 11 Kakamega | 51 | 1.91 | 1.91 | 19.71 |
| 12 Kericho | 28 | 1.05 | 1.05 | 20.76 |
| 13 Kiambu | 98 | 3.66 | 3.66 | 24.42 |
| 14 Kilifi | 60 | 2.24 | 2.24 | 26.66 |
| 15 Kirinyaga | 69 | 2.58 | 2.58 | 29.24 |
| 16 Kisii | 48 | 1.80 | 1.80 | 31.04 |
| 17 Kisumu | 66 | 2.47 | 2.47 | 33.51 |
| 18 Kitui | 72 | 2.69 | 2.69 | 36.20 |
| 19 Kwale | 24 | 0.90 | 0.90 | 37.10 |
| 20 Laikipia | 33 | 1.23 | 1.23 | 38.33 |
| 29 Murang'a | 74 | 2.77 | 2.77 | 58.45 |
| 30 Nairobi | 428 | 16.01 | 16.01 | 74.46 |
| 31 Nakuru | 108 | 4.04 | 4.04 | 78.50 |
| 32 Nandi | 21 | 0.79 | 0.79 | 79.28 |

| | | | | |
|------------------|-------------|---------------|---------------|--------|
| 33 Narok | 49 | 1.83 | 1.83 | 81.11 |
| 34 Nyamira | 31 | 1.16 | 1.16 | 82.27 |
| 35 Nyandarua | 17 | 0.64 | 0.64 | 82.91 |
| 36 Nyeri | 54 | 2.02 | 2.02 | 84.93 |
| 37 Pokot | 70 | 2.62 | 2.62 | 87.55 |
| 38 Samburu | 17 | 0.64 | 0.64 | 88.18 |
| 39 Siaya | 86 | 3.22 | 3.22 | 91.40 |
| 40 Taita Taveta | 25 | 0.93 | 0.93 | 92.33 |
| 41 Tana River | 11 | 0.41 | 0.41 | 92.74 |
| 42 Tharaka Nithi | 16 | 0.60 | 0.60 | 93.46 |
| 43 Trans Nzoia | 22 | 0.82 | 0.82 | 94.28 |
| 44 Turkana | 79 | 2.95 | 2.95 | 97.23 |
| 45 Uasin Gishu | 45 | 1.68 | 1.68 | 98.92 |
| 46 Vihiga | 24 | 0.90 | 0.90 | 99.81 |
| 47 Wajir | 5 | 0.19 | 0.19 | 100.00 |
| Total | 2674 | 100.00 | 100.00 | |

The total number of health care facilities was 1095, distributed among the 47 counties in Kenya, with Nairobi County having the most significant number of 428 (16%). However, in general, every county of the republic had a facility to follow up with clients who were diagnosed with DR-TB and have their results tallied to the NTLTP.

Table 3: Health sector treatment center distribution in Kenya

| Sector | Freq. | Percentage | Cum. |
|--------------------------|--------------|---------------|--------|
| Public | 2,225 | 83.21 | 83.21 |
| Private | 358 | 13.39 | 96.60 |
| Other Faith Based | 57 | 2.13 | 98.73 |
| Prisons | 34 | 1.27 | 100.00 |
| Total | 2,674 | 100.00 | |

Patients were generally enrolled for care among all models for the study period. Still, the numbers presented show that the public health model had a more significant treatment and care burden, as it enrolled and followed up to 80 % of all patients who had DR-TB from 2014 to 2019.

Table 4: Registration categories of DRTB patients in Kenya

| Valid | Freq. | Percentage | Valid | Cum. |
|---------------|-------------|---------------|---------------|--------|
| 1 FFT | 717 | 26.81 | 26.81 | 26.81 |
| 2 FRT | 203 | 7.59 | 7.59 | 34.41 |
| 3 LTFU | 224 | 8.38 | 8.38 | 42.78 |
| 4 New | 984 | 36.80 | 36.80 | 79.58 |
| 5 O | 19 | 0.71 | 0.71 | 80.29 |
| 6 R | 449 | 16.79 | 16.79 | 97.08 |
| 7 TI | 78 | 2.92 | 2.92 | 100.00 |
| Total | 2674 | 100.00 | 100.00 | |

It was evident that across the country, three categories accounted for close to 78% of the total drug-resistant tuberculosis cases in Kenya, including FFT (26.81%), New (36.80 %), and R (16.79 %).

5. Age Distribution

Patients who were enrolled were done with age categories. Thus, we categorized them into groups to see which ages were more affected

Table 5: Age category distribution in Kenya for DRTB patients

| | Freq. | Percentage | Valid | Cum. |
|-----------------------------|-------|------------|-------|-------|
| Valid 0 Young people | 638 | 23.86 | 23.86 | 23.86 |
| One young adult | 632 | 23.64 | 23.64 | 47.49 |
| Two middle-age | 845 | 31.60 | 31.60 | 79.09 |

3. Health sector distribution

The health sector is divided into the following categories: public, private, mission, and prison; hence, when it comes to drug-resistant TB management, the NLTP has allowed different players to recruit and treat cases diagnosed with DRTB following its guidelines.

4. Registration Categories of DRTB on Enrollment in Kenya

A review of patterns of resistance was done to establish types and the specifics of the resistance each patient had registered with where the following was recorded: New - N, Relapse - R, After the failure of Category 1 Treatment - FFT, After Failure of Category 11 Treatment - FRT, Transfer in - TI, Return after loss to follow up - LTFU, and Others - O.

by the disease. The types of patients who got registered for the treatment of drug-resistant tuberculosis were;

- Young people - aged below 20 years
- Young adults - aged between 20 to 40 years
- Middle-aged - aged between 40 to 50 years
- Old aged - aged above 50 years

| | | | | |
|-----------|------|--------|--------|--------|
| Three old | 559 | 20.91 | 20.91 | 100.00 |
| Total | 2674 | 100.00 | 100.00 | |

We see more middle-aged patients getting DR-TB infections than the other age groups from the numbers.


Table 6: Age distribution and DRTB resistance pattern in Kenya

| Age classes | Resistance Pattern | | | | | |
|--------------|--------------------|---------|-----|-----|-----|-----|
| | MDR XDR | Mono TB | PDR | Pre | RR | XDR |
| Young people | 201 | 166 | 13 | 2 | 246 | |
| Young adults | 233 | 136 | 13 | 4 | 231 | 1 |
| Middle age | 280 | 211 | 20 | 6 | 316 | 2 |
| Old | 145 | 162 | 18 | 4 | 212 | 5 |

The middle age group had a uniform distribution of different types of DR-TB, with the XDR type being the least reported among all age categories enrolled.

6. Sputum Testing for Presumptive Cases of DRTB in Kenya

As guided by the NLTP, all patients with coughs of any duration should undergo sputum testing of either AFB, Gene-Expert, LPA, or culture. This depends on the facility and availability of the required test.



Graph 1: AFB outcome results at month zero for DRTB patients in Kenya

A total of 2674 patients were screened for an AFB, of which 62 % had a positive AFB and 15% were negative. Up to 5 % of the patients

had missing records of the AFB report from those enrolled for DR-TB follow-up.

Table 7: Gene-Expert results tabulation for DRTB patients in Kenya

| Valid | Freq. | Percentage | Valid | Cum. |
|---|-------|------------|--------|--------|
| 1 Invalid/no result/error | 1 | 0.04 | 0.04 | 0.04 |
| 2 MTB detected Rifampicin resistance detected | 1672 | 62.53 | 65.59 | 65.63 |
| 3 MTB detected Rifampicin resistance | 7 | 0.26 | 0.27 | 65.91 |
| Indeterminate | | | | |
| 4 MTB detected Rifampicin resistance not detected | 464 | 17.35 | 18.20 | 84.11 |
| 5 MTB not detected | 48 | 1.80 | 1.88 | 85.99 |
| 6 Not Done | 357 | 13.35 | 14.01 | 100.00 |
| Total | 2549 | 95.33 | 100.00 | |
| Missing. | 125 | 4.67 | | |
| Total | 2674 | 100.00 | | |


62 % had MTB-RR type, of which 17% had not recorded any RR in their results but had been classified as DR-TB patients.

Table 8: Sputum Culture Outcome for DRTB patients in Kenya

| Valid | Freq. | Percentage | Valid | Cum. |
|--------------|-------|------------|--------|--------|
| 1 DNR | 31 | 1.16 | 1.44 | 1.44 |
| 2 ND | 386 | 14.44 | 17.95 | 19.39 |
| 3 NEG | 312 | 11.67 | 14.50 | 33.89 |
| 4 POS | 1422 | 53.18 | 66.11 | 100.00 |
| Total | 2151 | 80.44 | 100.00 | |
| Missing. | 523 | 19.56 | | |
| Total | 2674 | 100.00 | | |

For culture outcome, we could only account for 65% of the total enrolled patients who had taken a test. In contrast, cumulatively, we had the missing results, and the ones who were not done the culture

totaling 34 %, which is a very significant number to influence the pattern of spread to the community or affect treatment outcomes for the patients enrolled for care and treatment.



Graph 2: Graph of Gene-Expert and Sputum Culture Outcomes

Table 9: Resistance Pattern categories for sputum culture results

| Valid | Freq. | Percentage | Valid | Cum. |
|---------------------|-------|------------|--------|--------|
| 1 MDR | 859 | 32.12 | 32.70 | 32.70 |
| 2 Mono-resistant TB | 675 | 25.24 | 25.69 | 58.39 |
| 3 PDR | 64 | 2.39 | 2.44 | 60.83 |
| 4 Pre XDR | 16 | 0.60 | 0.61 | 61.44 |
| 5 RR | 1005 | 37.58 | 38.26 | 99.70 |
| 6 XDR | 8 | 0.30 | 0.30 | 100.00 |
| Total | 2627 | 98.24 | 100.00 | |
| Missing. | 47 | 1.76 | | |
| Total | 2674 | 100.00 | | |

From the data reviewed, it was evident that the resistance patterns indicated that MDR, RR, and Mono-resistance comprised up to 95 % of all the reported cases related to tuberculosis resistance. At the same time, the burden of Pre-XDR, XDR, and PDR was less than 3 %.

Table 10: Kenya’s distribution of DRTB resistance pattern per county

| County | Resistance Pattern | | | | | |
|-----------------|--------------------|-------------------|-----|---------|----|-----|
| | MDR | Mono-resistant TB | PDR | Pre XDR | RR | XDR |
| Baringo | 6 | 4 | | | 21 | |
| Bomet | 10 | 12 | 2 | | 11 | |
| Bungoma | 9 | 12 | | 2 | 21 | |
| Busia | 6 | 9 | 3 | 1 | 13 | |
| Elgeyo Marakwet | 7 | 5 | | | 3 | |
| Embu | 14 | 25 | 1 | | 16 | |
| Garissa | 94 | 33 | | | 7 | |
| Homa Bay | 29 | 10 | 1 | | 18 | |
| Isiolo | 6 | 18 | | | 1 | |
| Kajiado | 14 | 8 | | 1 | 14 | |
| Kakamega | 18 | 6 | 1 | | 26 | |
| Kericho | 9 | 8 | 1 | | 10 | |
| Kiambu | 14 | 32 | 2 | | 47 | |
| Kilifi | 10 | 16 | 1 | | 33 | |
| Kirinyaga | 18 | 26 | 4 | | 21 | |
| Kisii | 17 | 13 | | | 18 | |
| Kisumu | 25 | 25 | 2 | | 13 | |
| Kitui | 26 | 21 | 2 | | 19 | 2 |
| Kwale | 15 | 3 | | | 5 | |

| | | | | | | |
|---------------|-----|----|----|---|-----|---|
| Laikipia | 8 | 8 | 1 | | 16 | |
| Lamu | 2 | 2 | | | 2 | |
| Machakos | 29 | 35 | 2 | | 25 | 1 |
| Makueni | 12 | 14 | | | 23 | |
| Mandera | 2 | 2 | | | 5 | |
| Marsabit | 7 | 2 | | 1 | 3 | |
| Meru | 29 | 37 | 2 | 4 | 46 | |
| Migori | 15 | 4 | | | 25 | |
| Mombasa | 34 | 28 | 2 | 1 | 62 | |
| Murang'a | 11 | 20 | 3 | | 37 | |
| Nairobi | 192 | 79 | 15 | 2 | 131 | 4 |
| Nakuru | 31 | 30 | 2 | | 39 | 1 |
| Nandi | 2 | 8 | | 1 | 10 | |
| Narok | 5 | 19 | 4 | | 21 | |
| Nyamira | 16 | 3 | | | 10 | |
| Nyandarua | 3 | 3 | | | 11 | |
| Nyeri | 5 | 17 | 3 | | 29 | |
| Pokot | 25 | 12 | 4 | 2 | 27 | |
| Samburu | 7 | 1 | | | 9 | |
| Siaya | 17 | 27 | 1 | | 40 | |
| Taita Taveta | 6 | 5 | 1 | | 11 | |
| Tana River | | 2 | | 1 | 8 | |
| Test County | 3 | | | | | |
| Tharaka Nithi | 1 | 3 | 1 | | 8 | |
| Trans Nzoia | 7 | 3 | | | 10 | |
| Turkana | 15 | 16 | | | 48 | |
| Uasin Gishu | 20 | 3 | 2 | | 18 | |
| Vihiga | 7 | 6 | 1 | | 10 | |
| Wajir | 1 | | | | 4 | |

The distribution of tuberculosis resistance was similar to most counties with the same geographical and infrastructural developments, apart from Nairobi County, which had the most considerable number of cases of tuberculosis resistance in Kenya.

7. Cox PH Model of County conversion patterns for patients with DRTB in Kenya

They were stratified using County to detect which factors influenced differences in their conversion time. We used factors that uniformly affected all the countries bearing in the devolved health system in Kenya. The factors considered were Sector, Model of Care Registration group, Resistance Pattern, Sex MF, and Health Facility).

Table 11: Cox PH model for Sputum conversion among DRTB in Kenya

| | | | | | | |
|--|----------|----------|-------|-------|----------|----------|
| Stcox Sector_1 Sector_1 Model of Care_1 Registration group_1 Resistance Pattern_1 Sex MF_1 Health Facility_1 HI | | | | | | |
| > VStatus_1 BMI_Cat3 Age_reg_Cat2, strata (County) | | | | | | |
| Failure_d: Event_intsv_1 == 1 | | | | | | |
| Analysis time_t: Int_prd_M1 | | | | | | |
| id: Serial Number | | | | | | |
| Note: Sector_1 omitted because of collinearity | | | | | | |
| Refining estimates: | | | | | | |
| Iteration 0: log-likelihood = -3461.7378 | | | | | | |
| Stratified Cox regr. -- Breslow method for ties | | | | | | |
| No. of subjects = 1378 Number of obs = 1378 | | | | | | |
| No. of failures = 1041 | | | | | | |
| Time at risk = 9237 | | | | | | |
| LR chi2(9) = 82.43 | | | | | | |
| Log likelihood = -3461.7378 Prob > chi2 = 0.0000 | | | | | | |
| _t Haz. Ratio Std. Err. z P> z [95% Conf. Interval] | | | | | | |
| Sector_1 | .891345 | .0513249 | -2.00 | 0.046 | .7962187 | .9978361 |
| ModelOfCare_1 | .8310321 | .0676507 | -2.27 | 0.023 | .7084762 | .9747885 |
| Registrationgroup_1 | 1.018314 | .0186985 | 0.99 | 0.323 | .9823178 | 1.05563 |
| ResistancePattern_1 | 1.161405 | .0223266 | 7.78 | 0.000 | 1.118459 | 1.205999 |
| SexMF_1 | .8935478 | .0620721 | -1.62 | 0.105 | .7798073 | 1.023878 |

| | | | | | | |
|-----------------------------|----------|----------|-------|-------|----------|----------|
| HealthFacility_1 | 1.000027 | .0001058 | 0.26 | 0.797 | .9998199 | 1.000235 |
| HIVStatus_1 | 1.003756 | .0683429 | 0.06 | 0.956 | .8783589 | 1.147054 |
| BMI_Cat3 | 1.050001 | .0592816 | 0.86 | 0.387 | .9400087 | 1.172863 |
| Age_reg_Cat2 | .9791583 | .0402418 | -0.51 | 0.608 | .9033789 | 1.061295 |
| Stratified by County | | | | | | |

Test of proportional-hazards assumption

Time: Time

| | chi2 | df | Prob>chi2 |
|-------------|-------|----|-----------|
| global test | 21.99 | 9 | 0.0089 |

stptest, rank detail

Test of proportional-hazards assumption

Time: Rank(t)


| | rho | chi2 | df | Prob>chi2 |
|--------------|----------|-------|----|-----------|
| Sector_1 | 0.02258 | 0.59 | 1 | 0.4441 |
| o. Sector_1 | . | . | 1 | . |
| ModelOfCar~1 | -0.10428 | 10.96 | 1 | 0.0009 |
| Registrati~1 | 0.00131 | 0.00 | 1 | 0.9665 |
| Resistance~1 | -0.06576 | 5.12 | 1 | 0.0237 |
| SexMF_1 | -0.02500 | 0.66 | 1 | 0.4158 |
| HealthFaci~1 | 0.03012 | 0.94 | 1 | 0.3329 |
| HIVStatus_1 | 0.04631 | 2.25 | 1 | 0.1335 |
| BMI_Cat3 | -0.02661 | 0.76 | 1 | 0.3828 |
| Age_reg_Cat2 | -0.01877 | 0.36 | 1 | 0.5496 |
| Global test | | 21.63 | 9 | 0.0101 |

Only the Sector where patients got medication, the model of care, and resistance patterns significantly affected how counties could obtain different conversion times for the patients enrolled within their facilities for DR-TB treatment. The rest needed to be more significant to influence how counties would result in differences in conversion time.


8. Spatial Distribution of DR-TB in Kenya and the Associated Factors

We reviewed the country into regions because of the county effect across borders and then found how different factors were spatially distributed within the country. We had the Central region, the Northern region, the Coastal region, the Western region, and the Lakeside region.

Mono-resistance was uniformly distributed among the 47 counties of the Kenyan Republic. MDR mainly affected the Nyanza region, Nairobi, and Central areas of Kenya, and many Pre-XDR were majorly in the West.




Graph 3: Spatial Distribution of Resistance Patterns in DRTB in Kenya



Graph 4: Spatial Distribution Models of Care


Most patients in the country received care under the community-based method, evenly distributed within the 47 counties of the Kenyan Republic. In contrast, the facility-based care model was distributed within the town areas of the republic, indicating that town areas have more health facilities and more disease severity than rural

areas. The isolation-based model was still significant but remotely distributed within the counties.



Graph 5: Registration Group Spatial Distribution


The most significant burden of disease was from the ‘New cases, Loss to follow-up patients, and Failure of first-line Medication’ cases, which contributed the most considerable percentage of the total DR-TB cases in the Kenyan population and were evenly distributed within the 47 counties. Failure of second-line ant TB showed a major challenge, mostly happening within the significant towns of the Kenyan Republic.



Graph 6: Age Groups Spatial Distribution


Patients who were enrolled in DR-TB treatment comprised young adults, which we had grouped as being between 20 and 40 years old, and all counties uniformly represented this age bracket. The Middle-aged and older were sparsely distributed but majorly concentrated

within Major towns. The keynote is the distribution of the old and middle-aged population, which may indicate the care they require from these young adults who transmit the disease due to compromised immunity.



Graph 7: BMI Spatial Distribution at Enrollment

From the patients enrolled and the nature of the TB disease, most patients were underweight to malnutrition and were within the 47 counties of the Kenyan Republic. Still, the keynote is that some counties recorded patients as obese and overweight irrespective of the tuberculosis nature, making patients emaciated.



Graph 8: Treatment Outcome Spatial Distribution

The Kenyan population of patients who had DR-TB showed good treatment outcomes by either converting their sputum at the end of the follow-up period or completing their DR-TB mediation, and clinically, they were stable with no symptoms. Of note is that some counties in the western region and Rift Valley had consistently poor Outcomes.

Discussion

From this study, it was evident that drug-resistant tuberculosis was prevalent more within the urban areas compared to the rural setting, which was going with the natural transmission of the disease, which has been described by “long” stating that proximity to the source patient is also a determinant of transmission with overcrowding increasing the risk of disease spread [10]. From this, we saw more enrollments from the urban regions, which could have been due to the concentration of health facilities within the town areas compared to the rural areas, which had to have a centralized center for sending suspected cases for gene expert testing. With this, it was evident that they took more time before initiating patients on treatment than facilities with machines for doing the Gene-Expert within their premises. Additionally, we found that the common resistance type from the 47 counties was rifampicin resistance. This could have been attributed to the wide use of ant-TB with possible poor monitoring and follow-up, resulting in the high numbers of patients presenting with rifampicin resistance. The most affected group with tuberculosis was 40 to 50 years old, with men carrying a high burden of the disease compared to the female patients, which rhymed with WHO reporting; globally, men account for a higher proportion of notified TB cases of around 60-65% [11]. For the nutritional status, generally, the majority of the enrolled patients in all 47 counties had low BMI, indicating the need for nutritional supplementation within the treatment facilities handling DRTB patients. Supplementation then, we have a higher probability of having favorable treatment, which W.H.O. has asserted with the evident link between under-nutrition and active TB; nutrition screening, assessment, and management are integral components of TB treatment and care [12]. The treatment outcome was a success across the 47 counties. However, looking at the western and Nyanza regions, they had a significant number of poor outcomes, signifying death or loss to follow-up within the counties in those regions.

Conclusion

Given that health is a devolved function, there needs to be a more concerted effort to ensure there are laid down structures for coordinating the management of tuberculosis in general from the NLTP, which is under the national government and respective county health boards in practical and not in paper from which we can increase case detection rate with better treatment outcomes. Additionally, from the study, we have established a gap between diagnosis and the start of treatment where some counties take a longer time from sputum collection for gene-expert to culture reports; hence, if we had a regional reference lab with proper sample logistic system, it cut time taken to deliver samples to Nairobi for the marginalized counties leading to early treatment and less spread of the disease in the community.

Declarations

Ethics approval and consent to participate

Ethical clearance was obtained from the Kenyatta National Hospital/University of Nairobi Ethics Board under ethical review number P378|05|2019. A formal letter was also written to the national leprosy, tuberculosis, and lung disease program to abstract data from their system.

List of abbreviations

DR-TB - Drug-Resistant Tuberculosis

DST: Drug Susceptibility Testing

DS-TB: Drug Sensitive Tuberculosis

EPTB: Extra pulmonary Tuberculosis

MDR-TB: Multidrug-Resistant Tuberculosis

IGRA: Interferon Gamma Release Assay

INH: Isoniazid

IP - T: Isoniazid Preventive Therapy

DOT: Directly Observed Therapy

DRT - Drug Resistance Testing

DR-TB: Drug-Resistant Tuberculosis

DST: Drug Susceptibility Testing

DS-TB: Drug Sensitive Tuberculosis.

Data Availability

The data was abstracted from the National Tuberculosis, Leprosy, and Lung Disease Program (NTLD-P) Division under the Department of National Strategic Public Health Programs through the TIBU software, an electronic medical record module provided by the program

Authors' contributions

| Authors' contributions | MD | IO | AK | HK |
|----------------------------------|----|----|----|----|
| Research concept and design | √ | √ | √ | √ |
| Collection and assembly of data | √ | -- | -- | -- |
| Data analysis and interpretation | √ | -- | -- | -- |
| Writing the article | √ | -- | -- | -- |
| Critical revision of the article | √ | √ | √ | -- |
| Final approval of the article | √ | √ | √ | √ |
| Statistical analysis | √ | -- | -- | -- |

Conflict of Interest

There are no conflicts of interest in this article.

Funding Statement

The study had no external funding and was done through personal savings.

Acknowledgment

We want to acknowledge the National Leprosy, Tuberculosis, and Lung Disease for allowing us to use the data.

References

- [1] Williamson T, Mulaki A. Devolution of Kenya's health system - The role of Health Policy Project. Policy Br [Internet]. 2015;(January):8. Available from: https://www.healthpolicyproject.com/pubs/719_KenyaDevolutionBrief.pdf
- [2] NSP. The National Strategic Plan for Tuberculosis, Leprosy and Lung Health 2019 - 2023. 2023; Available from: <https://www.chskenya.org/wp-content/uploads/2019/04/National-Strategic-Plan-2019-2023.pdf>
- [3] Tuberculosis S. Stop tuberculosis. 2022;(April):2016-9.
- [4] Iacobino A, Fattorini L, Giannoni F. Drug-resistant tuberculosis 2020: Where we stand. Appl Sci. 2020;10(6):1-17.
- [5] Fu H, Lewnard JA, Frost I, Laxminarayan R, Arinaminpathy N. Modelling the global burden of drug-

- resistant tuberculosis avertable by a post-exposure vaccine. *Nat Commun* [Internet]. 2021;12(1):1-9. Available from: <http://dx.doi.org/10.1038/s41467-020-20731-x>
- [6] Coverage UH. Tuberculosis in the WHO African Region: 2023 progress update Tuberculosis in the WHO African Region: 2023 progress update. 2023;(September).
- [7] Naidoo K, Perumal R, Cox H, Mathema B, Loveday M, Ismail N, et al. The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis 2014; lessons from the South African experience. *Lancet Infect Dis* [Internet]. 2024 Apr 26; Available from: [https://doi.org/10.1016/S1473-3099\(24\)00144-0](https://doi.org/10.1016/S1473-3099(24)00144-0)
- [8] Mutabari D, Orowe I, Karanja A, Kipruto H. Insights of Bioinformatics Retrospective Analysis of Drug-Resistant Tuberculosis and the Associated Treatment Outcomes in Kenya. *Insights Bioinforma* [Internet]. 2022;2(1):21-9. Available from: <https://scholars.direct/Articles/bioinformatics/ibi-2-002.php?jid=bioinformatics>
- [9] Report GT. Kenya Tuberculosis Roadmap Overview, Fiscal Year 2021. 2023;1-5.
- [10] Long R, Divangahi M, Schwartzman K. Chapter 2: Transmission and pathogenesis of tuberculosis. *Can J Respir Crit Care, Sleep Med* [Internet]. 2022;6(S1):22-32. Available from: <https://doi.org/10.1080/24745332.2022.2035540>
- [11] Bierrenbach A. Background paper number 9 Estimating the burden of TB by age and sex: data availability, gaps and next steps. 2016;(9):1-16.
- [12] Summary E. WHO Guideline: Nutritional care and support for patients with tuberculosis i Nutritional care and support for patients with tuberculosis Executive Summary Guideline: WHO Guideline: Nutritional care and support for tuberculosis ii. *Nutr care Supports patients with Tuberc.* 2014; WHO/NMH/NH.



Published by AMMS Journal, this is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024